Drug Name	ZANTAC 150
Active Ingredient(s)	• RANITIDINE HYDROCHLORIDE
Form(s) and Strength(s) Available	• TABLET; ORAL:150MCG

Product Information / Press Release

  Qualitative and Quantitative Composition
ZANTAC 150mg Tablets: white film-coated, circular, biconvex tablets, engraved ZANTAC 150 on one face and GLAXO on the other. Each tablet contains ranitidine 150mg (as the hydrochloride).

ZANTAC Tablets are also indicated for:

• the treatment of duodenal ulcer and benign gastric ulcer associated with non-steroidal anti-inflammatory agents.
• the prevention of non-steroidal anti-inflammatory agent (including aspirin) associated duodenal ulcers in patients with a history of duodenal ulceration proven by endoscopy.
• the treatment of post-operative ulcer
• the treatment of chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but not associated with the above conditions.
• symptom relief in gastro-oesophageal reflux disease
• the treatment of oesophageal reflux disease
• the treatment of Zollinger-Ellison syndrome

ZANTAC Tablets are also indicated for the following conditions where reduction of gastric secretion and acid output is desirable:

• the prophylaxis of upper gastrointestinal haemorrhage from stress ulceration in seriously ill patients.
• the prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers.
• before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour.

CLINICAL PHARMACOLOGY